Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study - 20/12/22
, Micha Mandel, PhD b, Yinon M Bar-On, MSc c, Omri Bodenheimer, MSc d, Laurence Freedman, PhD e, Nachman Ash, MD d, e, Sharon Alroy-Preis, MD d, Amit Huppert, PhD f, g, †, Ron Milo, PhD c, †
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Background |
The BNT162b2 (Pfizer-BioNTech) two-dose vaccine regiment for children and the BNT162b2 third dose for adolescents were approved shortly before the SARS-CoV-2 omicron (B.1.1.529) outbreak in Israel. We aimed to estimate the effects of these vaccines on the rates of confirmed infection against the omicron variant in children and adolescents.
Methods |
In this observational cohort study, we extracted data for the omicron-dominated (sublineage BA.1) period. We compared rates of confirmed SARS-CoV-2 infection between children aged 5–10 years 14–35 days after receiving the second vaccine dose with an internal control group of children 3–7 days after receiving the first dose (when the vaccine is not yet effective). Similarly, we compared confirmed infection rates in adolescents aged 12–15 years 14–60 days after receiving a booster dose with an internal control group of adolescents 3–7 days after receiving the booster dose. We used Poisson regression, adjusting for age, sex, socioeconomic status, calendar week, and exposure.
Findings |
Between Dec 26, 2021, and Jan 8, 2022, we included 1 158 289 participants. In children aged 5–10 years, the adjusted rate of confirmed infection was 2·3 times (95% CI 2·0–2·5) lower in children who received a second dose than in the internal control group. The adjusted infection rate in children who received a second dose was 102 infections per 100 000 risk-days (94–110) compared with 231 infections per 100 000 risk-days (215–248) in the corresponding internal control cohort. In adolescents aged 12–15 years, the booster dose decreased confirmed infection rates by 3·3 times (2·8–4·0) compared with in the internal control group. The adjusted infection rate of the booster cohort was 70 per 100 000 risk-days (60–81) compared with 232 per 100 000 risk-days (212–254) in the internal control cohort.
Interpretation |
A recent two-dose vaccination regimen with BNT162b2 and a recent booster dose in adolescents substantially reduced the rate of confirmed infection compared with the internal control groups. Future studies are needed to assess the duration of this protection and protection against other outcomes such as paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 and long-COVID.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 1
P. 67-73 - janvier 2023 Retour au numéro
Article précédent
- Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study
- Megan Bardsley, Roger A Morbey, Helen E Hughes, Charles R Beck, Conall H Watson, Hongxin Zhao, Joanna Ellis, Gillian E Smith, Alex J Elliot
- Viral loads in clinical samples of men with monkeypox virus infection: a French case series
- Romain Palich, Sonia Burrel, Gentiane Monsel, Agathe Nouchi, Alexandre Bleibtreu, Sophie Seang, Vincent Bérot, Cécile Brin, Ariane Gavaud, Yara Wakim, Nagisa Godefroy, Antoine Fayçal, Yanis Tamzali, Thomas Grunemwald, Michel Ohayon, Eve Todesco, Valentin Leducq, Stéphane Marot, Vincent Calvez, Anne-Geneviève Marcelin, Valérie Pourcher
Bienvenue sur EM-consulte, la référence des professionnels de santé.